Paid information dissemination
Investorideas.com (www.investorideas.com newswire) a trusted funding platform for retail buyers reviews breaking
Medical Tech Inventory information for
Aethlon Medical, Inc.
(Nasdaq: AEMD), a clinical-stage medical therapeutic firm targeted on creating
merchandise to deal with most cancers and life-threatening viral infections for
which there is no such thing as a therapy.
Business commentary: SentimenTrader notes that healthcare has
quietly demonstrated sturdy defensive qualities, outperforming
the S&P 500 on 85% of the times the broader market posted
losses of 1% or extra over the previous yr. This resilience
underscores the sector’s potential as a dependable performer
throughout market downturns.
Aethlon Medical, Inc.
(Nasdaq: AEMD) immediately reported monetary outcomes for its fiscal yr ended March
31, 2026, and supplied an replace on current developments.
Abstract – Australian oncology research advances
into Cohort 3 as enrollment continues
Entered the third and closing dosing cohort of the Australian oncology
research, expanded the Hemopurifier mental property portfolio, and
maintained a concentrate on managing working bills.
Convention Name At the moment at 4:30 p.m. ET
Key Highlights
- Superior the Australian oncology research by way of completion of the primary two cohorts and entered the third and closing dosing cohort, representing a key medical milestone towards producing knowledge to tell future improvement and dosing technique.
- Lately handled the primary participant in Cohort 3 at Royal North Shore Hospital in Australia. The participant accomplished three Hemopurifier remedies over a one-week interval, marking continued enrollment momentum and execution of the research’s closing therapy arm.
- Superior preclinical analysis evaluating Hemopurifier functions in extra illness areas, together with rheumatoid arthritis and persistent kidney illness, supporting the growth of the platform’s potential addressable market past oncology and infectious illness.
- Continued to strengthen the mental property portfolio supporting the Hemopurifier platform, together with the issuance of patents in the USA and Europe protecting potential functions for lengthy COVID and different coronavirus-related situations, extending patent safety into the 2040s and enhancing long-term platform worth.
“Fiscal 2026 was a yr of significant execution for Aethlon as we
superior our Australian oncology research by way of the primary two cohorts
and not too long ago initiated Cohort 3.
Development into the ultimate cohort represents an vital
medical milestone as we work towards producing knowledge that will assist
outline the optimum therapy routine and information future improvement
selections.
We additionally strengthened the Hemopurifier platform by way of growth of
our mental property portfolio and development of preclinical
analysis supporting potential functions past oncology.
Mixed with our continued concentrate on managing working bills,
these achievements place us to pursue a number of value-creating
alternatives throughout our medical and analysis packages.” mentioned James Frakes, Chief Government Officer and Chief Monetary
Officer of Aethlon Medical.
Scientific Replace
Scientific Progress in Most cancers Trial
Enrollment and therapy of contributors in Cohort 2 of the
Australian oncology trial have been accomplished. An impartial Information
Security Monitoring Board reviewed the info, recognized no security
issues based mostly on its evaluation of accessible knowledge, and beneficial
advancing to the third and closing cohort. Screening is actively
underway on the three investigative websites for this closing cohort the place
3-6 contributors might be handled with 3 Hemopurifier periods throughout a
1-week interval. The primary participant in Cohort 3 of the research has been
enrolled and acquired three Hemopurifier remedies with none gadget
deficiencies or instant problems and is now within the follow-up
interval. Profitable enrollment and therapy of the primary participant in
Cohort 3 maintains the research’s medical momentum and strikes the Firm
nearer to finishing enrollment and producing knowledge from all deliberate
dosing regimens.
Serial Extracellular Vesicle and T cell measurements on contributors
in cohort 2 have been measured by the central lab on the College of
Sydney. Formal statistical analyses evaluating the results of the three
totally different Hemopurifier dosing regimens on these parameters might be
carried out by a CRO on the completion of the trial. This nine-to-18
affected person research is designed to judge the security and feasibility of the
Hemopurifier remedies and decide the suitable dosing in
contributors with stable tumors whose illness is secure or progressing
whereas on a therapy that features the anti-PD-1 brokers, Keytruda(R)
or Opdivo(R).
Different Current Developments
Throughout fiscal 2026, we strengthened our mental property
portfolio by way of the issuance of patents in each the USA
and Europe protecting potential functions of the Hemopurifier for
coronavirus-related situations, together with lengthy COVID and different
post-infection problems. These patents lengthen safety for
sure functions of the Hemopurifier into the 2040s and additional
strengthen the Firm’s mental property place surrounding the
Hemopurifier.
As well as, we superior our preclinical extracellular vesicle (EV)
analysis actions, together with research evaluating elimination of EVs in
plasma samples from sufferers with rheumatoid arthritis and persistent
kidney illness. These efforts assist the Firm’s ongoing analysis
of the Hemopurifier’s potential functions throughout a number of illness
classes and
could create future alternatives to increase the platform into giant
markets characterised by vital unmet medical want.
Individually, we continued our analysis of Hemopurifier compatibility
with a simplified blood therapy system being developed by Stavro
Medical. Preliminary testing assessing circulation charges and switch of fluid
by way of the Hemopurifier has been accomplished, and future research
evaluating elimination of surrogate markers for extracellular vesicles by
the Hemopurifier utilizing the system are into account. We consider
this method may increase potential therapy settings for the
Hemopurifier sooner or later and
could enhance the scalability and accessibility of therapy if
efficiently developed and validated.
Subsequent to fiscal year-end, an interview revealed in IEEE Spectrum
that includes Aethlon’s Chief Medical Officer and a doctor concerned in
the therapy of an Ebola virus illness affected person with the Hemopurifier
through the 2014 outbreak highlighted the Firm’s expertise with
Ebola therapy efforts. In reference to renewed public well being
curiosity surrounding current Ebola outbreaks, we additionally confirmed the
continued availability of our FDA-authorized expanded entry
(compassionate use) protocol and shared the protocol in addition to previous
in vitro and in vivo knowledge with organizations concerned in international and
U.S. rising pathogen preparedness efforts, together with the World Well being
Group’s R&D Blueprint skilled panel and the Nationwide Rising
Particular Pathogen Coaching and Training Middle.
Monetary Outcomes for the Fiscal Yr Ended March 31, 2026
As of March 31, 2026, the Firm had roughly $5.0 million in
money and money equivalents, offering sources to assist ongoing
medical and analysis actions.
Subsequent to fiscal year-end, the Firm strengthened its stability
sheet by elevating roughly $1.85 million in web proceeds by way of
its at-the-market program.
Consolidated working bills declined 21.9% year-over-year to
roughly $7.3 million, reflecting continued expense self-discipline and
operational effectivity whereas advancing the Firm’s medical and
analysis priorities in comparison with $9.3 million for the fiscal yr ended
March 31, 2025. The lower was primarily resulting from $1.1 million
discount in payroll and associated bills, a $500,000 discount in
normal and administrative bills and a $400,000 discount in
skilled charges.
Per the discount in working bills, the working
loss for the fiscal yr decreased to roughly $7.3 million for
fiscal 2026 from $9.3 million within the prior fiscal yr.
Different revenue was roughly $142,000 for the fiscal yr ended
March 31, 2026, primarily reflecting curiosity revenue earned on money
balances, in comparison with different expense of roughly $4 million within the
prior fiscal yr. The prior-year quantity included roughly $4.7
million of non-cash financing-related costs.
Internet loss attributable to our widespread stockholders was $7.2 million for
the fiscal yr ended March 31, 2026, in comparison with web lack of $13.4
million for the fiscal yr ended March 31, 2025.
Convention Name
Administration will host a convention name immediately, Wednesday, June 10,
2026, at 4:30 p.m. ET to evaluation the Firm’s monetary outcomes and
current company developments. Following administration’s formal remarks,
there might be a question-and-answer session.
events can register for the convention name by navigating
to
https://dpregister.com/sreg/10209612/1042263e8ec. Please be aware that registered contributors will obtain their dial-in
quantity upon registration.
events with out web entry or unable to pre-register
could dial in by calling:
PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442
All callers ought to ask for the Aethlon Medical, Inc. convention name.
A replay of the decision might be obtainable roughly one hour after
the tip of the decision by way of July 10, 2026. The replay may be accessed
through Aethlon Medical’s web site or by dialing 1-855-669-9658 (USA or
Canada) or 1-412-317-0088 (worldwide) or Canada toll free at
1-855-669-9658. The replay convention ID quantity is 7883435.
Concerning the Hemopurifier(R)
The Aethlon Hemopurifier is an investigational medical gadget designed
to take away enveloped viruses and tumor-derived extracellular vesicles
(EVs) from circulation. It’s used extracorporeally with a blood pump
and combines plasma separation, measurement exclusion, and affinity binding
utilizing a plant lectin resin that targets mannose-rich surfaces discovered on
EVs and viruses. EVs launched by stable tumors are believed to play a
function in metastasis and the resistance to immunotherapies and
chemotherapy. Removing of enveloped viruses and extracellular vesicles
has been demonstrated in each in vitro research and human topics.
The Hemopurifier holds a U.S. Meals and Drug Administration Breakthrough
Gadget Designation for:
The therapy of people with superior or metastatic most cancers
unresponsive to or illiberal of standard-of-care remedy; and the
therapy of life-threatening viruses not addressed with authorized
therapies.
Full information and financials from AEMD
Extra information on AEMD at Investorideas.com
Get Information Alerts on Aethlon Medical
Analysis biotech shares at Investorideas.com:
https://www.investorideas.com/Firms/RenewableEnergy/stock_list.asp
Join free inventory information alerts at Investorideas.com:
https://www.investorideas.com/Assets/E-newsletter.asp
About Investorideas.com – Huge Investing Concepts
Investorideas.com
is a trusted platform for retail buyers, serving as a hub for
revolutionary investing concepts for over 25 years. Recognized for its pioneering
protection of sectors like mining, cleantech, protection, and water shares,
the corporate and its executives have been featured in high-profile
media shops for its experience. Investorideas.com is at all times on the
forefront of funding traits, providing protection of numerous
industries corresponding to AI, mining, and tech. With a mission to empower
buyers, the corporate offers breaking information, sector-focused
articles, podcasts, and unique interviews with main specialists. In
addition, its award-winning branded content material, AI-driven brief movies,
and podcasts spotlight key investing insights and have outstanding
trade leaders.
Investor Concepts digital promoting and visitor posts service:
https://www.investorideas.com/Promote/
Comply with us on X @investorideas @stocknewsbites
Comply with us on
Fb
https://www.fb.com/Investorideas
Comply with Investorideas and the Exploring Mining Podcast on YouTube
https://www.youtube.com/c/Investorideas
Buyers keep forward by signing up free of charge inventory information alerts at
Investorideas.com
Be a part of our free Telegram neighborhood
https://t.me/+o8DxSAgeNCk2ZGVh
Contact us for more information
Name 800 665 0411
Aethlon Medical, Inc. (Nasdaq: AEMD) is a paid featured medical tech
inventory on Investorideas.com.
Extra disclosure: Investorideas.com is a digital writer of third social gathering sourced information,
articles and fairness analysis in addition to creates unique content material,
together with video, interviews and articles. Unique content material created by
investorideas is protected by copyright legal guidelines aside from syndication
rights. Our website doesn’t make suggestions for purchases or sale of
shares, companies or merchandise. Nothing on our websites ought to be construed
as a suggestion or solicitation to purchase or promote merchandise or securities. All
investing entails threat and potential losses. This website is at present
compensated for information publication and distribution, social media and
advertising, content material creation and extra.
Extra disclosure: Contact administration and IR of every firm instantly concerning particular
questions.
